Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 15/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2979588 | 0.92 | TLR8 (0.47) | CHRM3ACHEAKR1B1HDAC1HDAC6 | |
| SCHEMBL2970778 | 0.91 | BAZ2B (0.42) | CHRM3ACHEAKR1B1HDAC1HDAC6 | |
| SCHEMBL2979124 | 0.90 | HDAC6 (0.50) | CHRM3AKR1B1HDAC1HDAC6 | |
| SCHEMBL2976043 | 0.90 | MAP3K11 (0.42) | CHRM3ACHEAKR1B1HDAC1HDAC6 | |
| SCHEMBL2978935 | 0.90 | ACHE (0.40) | CHRM3ACHEAKR1B1HDAC1HDAC6 | |
| SCHEMBL2978678 | 0.88 | SIRT2 (0.43) | ACHEAKR1B1HDAC1HDAC6SIRT2 | |
| SCHEMBL8259645 | 0.88 | TBK1 (0.43) | — | |
| SCHEMBL2978156 | 0.88 | CHRM3 (0.42) | CHRM3ACHEHDAC1HDAC6 | |
| SCHEMBL2980332 | 0.86 | HDAC1 (0.47) | ACHEAKR1B1HDAC1HDAC6 | |
| SCHEMBL5316177 | 0.85 | AURKA (0.41) | ACHESIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772245-B2 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| EP-1851219-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF HISTONE DEACETYLASE | Miikana Therapeutics, Inc. (US) | 2007-11-07 | — | — | EP | disclosed |
| US-20060199829-A1 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS, INC. | 2006-09-07 | — | — | US | disclosed |
| WO-2006088949-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF HISTONE DEACETYLASE | MIIKANA THERAPEUTICS, INC. (US) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199829-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC2, HDAC11 | CHRM3 4721/4885ACHE 4080/4885AKR1B1 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.